Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.

MLA

Qiang, Shi Qing, et al. “Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.” Asian Pacific Journal of Cancer Prevention : APJCP, vol. 22, no. 8, Aug. 2021, pp. 2529–39. EBSCOhost, https://doi.org/10.31557/APJCP.2021.22.8.2529.

APA

Qiang, S. Q., Qin, G. C., Jing, L., Qiang, F. Z., Mei, Q. H., & Long, C. D. (2021). Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway. Asian Pacific Journal of Cancer Prevention : APJCP, 22(8), 2529–2539. https://doi.org/10.31557/APJCP.2021.22.8.2529

Chicago

Qiang, Shi Qing, Gao Chao Qin, Li Jing, Feng Zi Qiang, Qin Hong Mei, and Chen Di Long. 2021. “Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.” Asian Pacific Journal of Cancer Prevention : APJCP 22 (8): 2529–39. doi:10.31557/APJCP.2021.22.8.2529.